An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
NCT ID: NCT01939548
Last Updated: 2016-08-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
240 participants
INTERVENTIONAL
2013-10-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
NCT01175135
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
NCT02418819
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
NCT00463372
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
NCT01235520
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
NCT02019329
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-02545920 (5mg)
PF-02545920
PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
Placebo
Placebo
Placebo BID until the Week 12 visit
PF-02545920 (15mg)
PF-02545920
PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-02545920
PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
Placebo
Placebo BID until the Week 12 visit
PF-02545920
PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
* Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.
Exclusion Criteria
* Subjects with schizophrenia that have not responded at all to current treatment.
* Pregnant or nursing females, and females of child bearing potential.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama, United States
Woodland International Research Group, INC
Little Rock, Arkansas, United States
Comprehensive Clinical Development, Inc.
Cerritos, California, United States
ProScience Research Group
Culver City, California, United States
Synergy Clinical Research of Escondido
Escondido, California, United States
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States
Pacific Research Partners
Oakland, California, United States
Excell Research, Inc.
Oceanside, California, United States
Neuropsychiatric Research Center of Orange County
Orange, California, United States
CiTrials
Riverside, California, United States
CNRI-San Diego, LLC
San Diego, California, United States
Sharp Mesa Vista Hospital
San Diego, California, United States
Collaborative Neuroscience Network, Inc.
Torrance, California, United States
Bliss Basement Pharmacy
Hartford, Connecticut, United States
Institute of Living
Hartford, Connecticut, United States
Yale University
New Haven, Connecticut, United States
Comprehensive Clinical Development
Washington D.C., District of Columbia, United States
Florida Clinical Research Center, LLC
Bradenton, Florida, United States
Florida Clinical research Center, LLC
Brandenton, Florida, United States
Innovative Clinical Research, Inc.
Lauderhill, Florida, United States
Medical Research Group of Central Florida
Sanford, Florida, United States
Comprehensive Clinical Development, Inc.
Atlanta, Georgia, United States
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, United States
Chinmay K. Patel, DO
Hoffman Estates, Illinois, United States
Behavioral Health Care Associates
Schaumburg, Illinois, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Louisiana Clinical Research
Shreveport, Louisiana, United States
CBH Health, LLC
Rockville, Maryland, United States
Psychiatric Care & Research Center
O'Fallon, Missouri, United States
St. Louis Clinical Trials/The Summit@Creve Coeur
St Louis, Missouri, United States
Altea Research
Las Vegas, Nevada, United States
Comprehensive Clinical Development
Jamaica, New York, United States
Manhattan Psychiatric Center's 125th St. Clinic
New York, New York, United States
Manhattan Psychiatric Center
Ward's Island, New York, United States
Midwest Clinical Research Center, LLC
Dayton, Ohio, United States
Cutting Edge Research Group
Oklahoma City, Oklahoma, United States
Research Strategies of Memphis, LLC
Memphis, Tennessee, United States
FutureSearch Trials
Austin, Texas, United States
Community Clinical Research, Inc
Austin, Texas, United States
Futuresearch Trials of Dallas
Dallas, Texas, United States
Pillar Clinical Research LLC
Dallas, Texas, United States
InSite Clinical Research
DeSoto, Texas, United States
Psychiatric and Behaviorial Solutions
Salt Lake City, Utah, United States
Lifetree Clinical Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Targum SD, Cara Pendergrass J, Toner C, Zumpano L, Rauh P, DeMartinis N. Impact of BPRS interview length on ratings reliability in a schizophrenia trial. Eur Neuropsychopharmacol. 2015 Mar;25(3):312-8. doi: 10.1016/j.euroneuro.2014.11.023. Epub 2014 Dec 13.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A8241019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.